Tags

Type your tag names separated by a space and hit enter

Weight gain in a controlled study of risperidone in children, adolescents and adults with mental retardation and autism.
J Child Adolesc Psychopharmacol. 2001 Fall; 11(3):229-38.JC

Abstract

As part of an ongoing, prospective, ABA design, double-blind crossover study of risperidone versus placebo for the treatment of aggressive, destructive and self-injurious behavior in persons aged 6-65 years with mental retardation (MR) and autism, we measured the weight of 19 subjects at each study visit. We compared mean weight gain during the 16-week acute phase and 24-week open maintenance phase with that during the initial and middle placebo phases statistically, using a linear mixed model procedure. Results of the linear mixed model analysis showed that relative weight gain observed during the acute and maintenance drug phases was significantly greater than that observed during the initial and middle placebo phases respectively (p = .0001 and p = .0001). Over approximately a year, children aged 8-12 (n = 5) gained a mean of 8.2 kg (range = 2.7-17.7 kg); adolescents (n = 6) aged 13-16 gained a mean of 8.4 kg (range 3.6-15.5 kg); adults aged 21-51 (n = 8) gained a mean of 5.4 kg (range 0-9.5 kg). Weight gain observed in this controlled study of risperidone treatment in children, adolescents, and adults with MR and autism was significant. It may be greater in this population than in others reported and in this study was not limited to an acute effect only. Rate of weight gain diminished rapidly on tapering and stopping the drug. Further studies are urgently needed, including those incorporating diet and exercise programming.

Authors+Show Affiliations

Department of Psychiatry and Behavioral Sciences, University of Kansas Medical Center, Kansas City 66160, USA. jhelling@kumc.eduNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Controlled Clinical Trial
Journal Article
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

11642473

Citation

Hellings, J A., et al. "Weight Gain in a Controlled Study of Risperidone in Children, Adolescents and Adults With Mental Retardation and Autism." Journal of Child and Adolescent Psychopharmacology, vol. 11, no. 3, 2001, pp. 229-38.
Hellings JA, Zarcone JR, Crandall K, et al. Weight gain in a controlled study of risperidone in children, adolescents and adults with mental retardation and autism. J Child Adolesc Psychopharmacol. 2001;11(3):229-38.
Hellings, J. A., Zarcone, J. R., Crandall, K., Wallace, D., & Schroeder, S. R. (2001). Weight gain in a controlled study of risperidone in children, adolescents and adults with mental retardation and autism. Journal of Child and Adolescent Psychopharmacology, 11(3), 229-38.
Hellings JA, et al. Weight Gain in a Controlled Study of Risperidone in Children, Adolescents and Adults With Mental Retardation and Autism. J Child Adolesc Psychopharmacol. 2001;11(3):229-38. PubMed PMID: 11642473.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Weight gain in a controlled study of risperidone in children, adolescents and adults with mental retardation and autism. AU - Hellings,J A, AU - Zarcone,J R, AU - Crandall,K, AU - Wallace,D, AU - Schroeder,S R, PY - 2001/10/20/pubmed PY - 2002/1/25/medline PY - 2001/10/20/entrez SP - 229 EP - 38 JF - Journal of child and adolescent psychopharmacology JO - J Child Adolesc Psychopharmacol VL - 11 IS - 3 N2 - As part of an ongoing, prospective, ABA design, double-blind crossover study of risperidone versus placebo for the treatment of aggressive, destructive and self-injurious behavior in persons aged 6-65 years with mental retardation (MR) and autism, we measured the weight of 19 subjects at each study visit. We compared mean weight gain during the 16-week acute phase and 24-week open maintenance phase with that during the initial and middle placebo phases statistically, using a linear mixed model procedure. Results of the linear mixed model analysis showed that relative weight gain observed during the acute and maintenance drug phases was significantly greater than that observed during the initial and middle placebo phases respectively (p = .0001 and p = .0001). Over approximately a year, children aged 8-12 (n = 5) gained a mean of 8.2 kg (range = 2.7-17.7 kg); adolescents (n = 6) aged 13-16 gained a mean of 8.4 kg (range 3.6-15.5 kg); adults aged 21-51 (n = 8) gained a mean of 5.4 kg (range 0-9.5 kg). Weight gain observed in this controlled study of risperidone treatment in children, adolescents, and adults with MR and autism was significant. It may be greater in this population than in others reported and in this study was not limited to an acute effect only. Rate of weight gain diminished rapidly on tapering and stopping the drug. Further studies are urgently needed, including those incorporating diet and exercise programming. SN - 1044-5463 UR - https://www.unboundmedicine.com/medline/citation/11642473/Weight_gain_in_a_controlled_study_of_risperidone_in_children_adolescents_and_adults_with_mental_retardation_and_autism_ L2 - https://www.liebertpub.com/doi/full/10.1089/10445460152595559?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -